Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer | Zendy

Shari Goldfarb | Zendy; Volkan Turan | Zendy; Giuliano Bedoschi | Zendy; Enes Taylan | Zendy; Nadia Abdo | Zendy; Tessa Cigler | Zendy; Heejung Bang | Zendy; Sujita Patil | Zendy; Maura N. Dickler | Zendy; Kutluk Oktay | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer

Author(s) -

Shari Goldfarb,

Volkan Turan,

Giuliano Bedoschi,

Enes Taylan,

Nadia Abdo,

Tessa Cigler,

Heejung Bang,

Sujita Patil,

Maura N. Dickler,

Kutluk Oktay

Publication year - 2020

Publication title -

breast cancer research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.908

H-Index - 154

eISSN - 1573-7217

pISSN - 0167-6806

DOI - 10.1007/s10549-020-05933-7

Subject(s) - tamoxifen , ovarian reserve , anti müllerian hormone , breast cancer , medicine , chemotherapy , oncology , anthracycline , regimen , cyclophosphamide , fertility preservation , chemotherapy regimen , gynecology , cancer , hormone , fertility , pregnancy , infertility , biology , population , environmental health , genetics

To determine the longitudinal impact of adjuvant chemotherapy and tamoxifen-only treatments on the reproductive potential of women with breast cancer by using a sensitive ovarian reserve marker anti-Mullerian hormone (AMH) as a surrogate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research